Get the Stockscreener App
72.70
4.33%
3.02
After Hours:
72.70
Ionis Pharmaceuticals Inc stock is traded at $72.70, with a volume of 2.94M.
It is up +4.33% in the last 24 hours and down -10.17% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
See More
Previous Close:
$69.68
Open:
$70.68
24h Volume:
2.94M
Relative Volume:
1.33
Market Cap:
$12.01B
Revenue:
$943.38M
Net Income/Loss:
$-380.99M
P/E Ratio:
-29.47
EPS:
-2.4667
Net Cash Flow:
$-325.67M
1W Performance:
+1.44%
1M Performance:
-10.17%
6M Performance:
+15.45%
1Y Performance:
+125.29%
1-Day Range:
$70.68
$73.61
1-Week Range:
$68.90
$73.61
52-Week Range:
$23.95
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
72.70 | 11.51B | 943.38M | -380.99M | -325.67M | -2.4667 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Overweight |
| Oct-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-26-25 | Upgrade | Goldman | Sell → Neutral |
| Sep-03-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-31-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-01-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-07-25 | Initiated | H.C. Wainwright | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Neutral |
| Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-16-24 | Resumed | Jefferies | Buy |
| Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
IONS: HC Wainwright & Co. Raises Price Target to $120 | IONS Sto - GuruFocus
Stifel raises Ionis Pharmaceuticals price target on drug pricing By Investing.com - Investing.com India
IONS: Needham Raises Price Target for Ionis Pharmaceuticals | IO - GuruFocus
Needham & Company LLC Issues Positive Forecast for Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $120.00 at HC Wainwright - MarketBeat
Wolfe Research reiterates Ionis stock rating on pricing strategy - Investing.com
Patterns Watch: Why is Ionis Pharmaceuticals Inc stock going upAnalyst Downgrade & Long Hold Capital Preservation Plans - baoquankhu1.vn
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS), GE Healthcare Technologies Inc (GEHC) and Insmed (INSM) - The Globe and Mail
Aug Big Picture: Does Ionis Pharmaceuticals Inc outperform in volatile marketsSwing Trade & Weekly Chart Analysis and Guides - baoquankhu1.vn
When Insider Selling Is a Good Thing: 2 Stocks to Watch - Investing.com
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug - TradingView
FDA accepts zilganersen application for Alexander disease review By Investing.com - Investing.com Canada
Ionis Pharmaceuticals (IONS) Gains FDA Priority Review for Zilga - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $412,477.64 in Stock - MarketBeat
Ionis Pharma EVP Schneider sells $412k in shares By Investing.com - Investing.com South Africa
Ionis Pharma EVP Schneider sells $412k in shares - Investing.com
Ionis gains priority review for zilganersen for Alexander disease - MSN
Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review - BioSpace
FDA Prioritizes Review of Ionis Pharmaceuticals' Drug for Alexan - GuruFocus
Ionis Pharmaceuticals, Inc. recently announced that its New Drug Application (NDA) for Zilganersen, a new treatment developed for Alexander disease (AxD), has been granted Priority Review designation by the U.S. Food and Drug Administration (FDA). - Bitget
FDA accepts zilganersen application for Alexander disease review - Investing.com
Ionis Pharmaceuticals Inc at Leerink Global Healthcare Conference Transcript - GuruFocus
Ionis Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Ionis Board Shakeup And Valuation Gap Draw Investor Attention - Yahoo Finance
Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart
Ionis Pharmaceuticals' Peak Olezarsen Revenues Are Likely Very Conservative (NASDAQ:IONS) - Seeking Alpha
IONS Stock Price, Quote & Chart | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill
Affiliate files Form 144 to sell shares — IONS (NASDAQ: IONS) - Stock Titan
Why Ionis Pharmaceuticals’ (IONS) 2026 catalyst pipeline supported Leerink’s higher target - MSN
Hudson Bay Capital Management LP Decreases Stock Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Groupama Asset Managment - MarketBeat
Insider Sell: Elizabeth Hougen Sells 225,220 Shares of Ionis Pha - GuruFocus
Did Ionis Pharmaceuticals' (IONS) Board Refresh and Return of Peter Reikes Just Shift Its Investment Narrative? - simplywall.st
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 215,048 Shares of Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $744,692.12 in Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ: IONS) CFO sells 225,220 shares after option exercises - Stock Titan
Why Ionis Pharmaceuticals’ (IONS) 2026 Catalyst Pipeline Supported Leerink’s Higher Target - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), BioMarin Pharmaceutical (BMRN) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS), Airsculpt Technologies (AIRS) and NRX Pharmaceuticals (NRXP) - The Globe and Mail
BlueCrest Capital Management Ltd Makes New Investment in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Alpine Global Management LLC Acquires 30,463 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Retail Trends: Can Ionis Pharmaceuticals Inc outperform in the next rally2026 Rallies & Stock Market Timing Techniques - baoquankhu1.vn
Bamco Inc. NY Makes New $1.64 Million Investment in Ionis Pharmaceuticals, Inc. $IONS - National Today
Goldman Sachs Upgrades Ionis Pharmaceuticals (IONS) - MSN
IONS (IONS) Form 144 notices proposed resale of 225,200 shares - Stock Titan
Ionis Pharmaceuticals (IONS) Among Most Oversold Healthcare Stocks - GuruFocus
Ionis Pharmaceuticals, Inc. $IONS Shares Purchased by Jain Global LLC - MarketBeat
BlueCrest Capital Management Ltd Takes Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Cinctive Capital Management LP Invests $11.37 Million in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Boone Capital Management LLC Takes $27.34 Million Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Baker BROS. Advisors LP Makes New $37.08 Million Investment in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):